23567-67-1

Basic information

• Product Name: p-(1,2,3,4-thiatriazol-5-ylamino)phenol
• Synonyms: p-(1,2,3,4-thiatriazol-5-ylamino)phenol;4-(1,2,3,4-Thiatriazole-5-ylamino)phenol
• CAS NO: 23567-67-1
• Molecular Formula: C₇H₆N₄OS
• Molecular Weight: 194.21374
• EINECS: 245-745-4
• Mol File: 23567-67-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 321°Cat760mmHg
• Flash Point: 147.9°C
• Appearance: /
• Density: 1.63g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.751
• CAS DataBase Reference: p-(1,2,3,4-thiatriazol-5-ylamino)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: p-(1,2,3,4-thiatriazol-5-ylamino)phenol(23567-67-1)
• EPA Substance Registry System: p-(1,2,3,4-thiatriazol-5-ylamino)phenol(23567-67-1)

Safety Data

• Hazardous Substances Data: 23567-67-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H6N4OS/c12-6-3-1-5(2-4-6)8-7-9-10-11-13-7/h1-4,12H,(H,8,9,11)

Upstream product

• 30714-45-5 ammonium p-hydroxydithiocarbanilate 
• 123-30-8 4-amino-phenol 
• 68372-10-1 4-(4-hydroxyphenyl)-3-thiosemicarbazide 

Downstream Products

• 548765-59-9 methyl-phenyl-carbamic acid 4-([1,2,3,4]thiatriazol-5-ylamino)-phenyl ester 
• 52431-78-4 1-(4-hydroxyphenyl)-1H-tetrazole-5-thiol 

Relevant articles and documents

Synthesis, in vivo effects, metabolism, and excretion of 5 (p hydroxyanilino) 1,2,3,4 thiatriazole in the beagle dog

Trained normal and hypertensive beagle dogs were given tritiated 5 (p hydroxyanilino) 1,2,3,4 thiatriazole orally (30 mg/kg) and intravenously (20 mg/kg). Pasma levels of radioactivity as well as blood pressure and heart rate were measured concomitantly at various times following drug administration. The maximum hypotensive effect occurred 2 hr after intravenous administration and 4 to 8 hr after oral administration. This maximum effect did not correlate with maximum plasma levels of parent drug or metabolic, suggesting that a single agent may not be responsible for the hypotensive effect; a secondary mechanism may be involved. Excretion of radioactivity was followed for 5 to 6 days after administration. Biliary secretion of parent drug or its metabolites was indicated when 9 to 17% of intravenously administered drug radioactivity was excreted via the feces. Examination of urinary metabolites from each dog showed unchanged parent drug 5.7 to 20.7% (iv), 18.6 to 20.2% (oral); p aminophenol 45.9 to 66.5% (iv), 40.7 to 45.5% (oral). Urine from one dog was examined for other metabolites, and the following were found: p hydroxyphenylthiourea, 3.2 to 5.6%; p hydroxyphenylurea, 7.1 to 10.5%; APAP, 1.5 to 1.8%; unknown metabolite, 16.2 to 23.9%.

Preparation of some 1,2,3,4-tetrazoles

-